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ABSTRACT  
BACKGROUND 
GMZ2 is a recombinant protein malaria vaccine, comprising two blood-stage antigens of 
Plasmodium falciparum, glutamate-rich protein and merozoite surface protein 3. We assessed 
efficacy of GMZ2 in children in Burkina Faso, Gabon, Ghana and Uganda. 
 
METHODS 
Children 12–60 months old were randomized to receive three injections of either 100 μg 
GMZ2 adjuvanted with aluminum hydroxide or a control vaccine (rabies) four weeks apart 
and were followed up for six months to measure the incidence of malaria defined as fever or 
history of fever and a parasite density ≥5000/µL. 
 
RESULTS 
A cohort of 1849 children were randomized, 1735 received three doses of vaccine (868 
GMZ2, 867 control-vaccine).  There were 641 malaria episodes in the GMZ2/Alum group 
and 720 in the control group. In the ATP analysis, vaccine efficacy (VE), adjusted for age 
and site was 14% (95% confidence interval [CI]: 3.6%, 23%, p-value=0.009). In the ITT 
analysis, age-adjusted VE was 11.3% (95% CI 2.5%,19%, p-value=0.013). VE was higher in 
older children. In GMZ2-vaccinated children, the incidence of malaria decreased with 
increasing vaccine-induced anti-GMZ2 IgG concentration. There were 32 cases of severe 
malaria (18 in the rabies vaccine group and 14 in the GMZ2 group), VE 27% (95%CI -44%, 
63%). 
 
CONCLUSIONS 
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GMZ2 is the first blood-stage malaria vaccine to be evaluated in a large multicenter trial. 
GMZ2 was well tolerated and immunogenic, and reduced the incidence of malaria, but 
efficacy would need to be substantially improved, using a more immunogenic formulation, 
for the vaccine to have a public health role. 
 
Keywords: Phase 2 clinical trial, GMZ2, GLURP, MSP3, vaccine, antibody, efficacy, 
Plasmodium falciparum. 
 
  
Highlights: 
• The GMZ2 fusion protein consist of the non-repeat region of falciparum GLURP 
genetically fused to a MSP3 fragment 
• The GMZ2 fusion protein elicited functional antibodies in phase 1 studies 
• In the ATP analysis, vaccine efficacy adjusted for age and site was 14% (95% CI: 
3.6%, 23%) 
• Vaccine efficacy was higher in older children 
• In GMZ2-vaccinated children, the incidence of malaria decreased with increasing 
vaccine-induced anti-GMZ2 IgG concentration 
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1. Introduction  
Malaria caused by Plasmodium falciparum infection continues to be a leading cause of 
morbidity and mortality in children in sub-Saharan Africa [1]. Following repeated infections, 
non-sterile immunity develops that protects against more severe forms of the disease [2]. This 
type of semi-immunity is directed against the asexual blood-stage of the parasite. Passive 
transfer experiments have shown that antibodies play an important role in this immunity, by 
inhibiting excessive parasite replication [3, 4]. In principle, all stages of parasite development 
within the human body are potential vaccine targets: the pre-erythrocytic-stage, (parasites 
inoculated by infected mosquitoes, circulate briefly and then develop in liver cells); the 
asexual blood-stage, which causes disease symptoms and complications; and the sexual-
stages, when parasites differentiate into male and female gametes. The RTS,S vaccine, the 
first malaria vaccine to be evaluated in a phase 3 trial, elicits immunity against pre-
erythrocytic stages and has shown consistent protection in clinical trials [5, 6]. The final 
results of the RTS,S phase 3 trial are an important landmark, but protective efficacy was 
moderate, and waned [7]. A number of approaches are being pursued to develop improved, 
second generation vaccines. These include asexual blood-stage vaccines, which seek to limit 
but not prevent parasitaemia. However, blood stage candidates that have been evaluated in 
clinical trials have shown no protection [8, 9] or protection limited to the vaccine parasite 
strain [10, 11]. Identifying the protective epitopes, and the variability in the antigens that are 
exposed to the immune system have posed major problems in the development of malaria 
vaccine candidates [12]. These challenges have led to the proposal that for a next generation 
malaria vaccine RTS,S should be complemented with conserved antigens from the blood-
stage [13]. Some evidence of protection against blood-stage infection was seen in post-hoc 
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analyses of a phase 1 trial with a conserved part of the Merozoite Surface Protein 3 (MSP3) 
in Burkina Faso, suggesting a MSP3 vaccine might be effective [14]. 
 
The recombinant fusion protein, GMZ2, contains conserved fragments of two P. falciparum 
asexual blood-stage antigens, Glutamate-Rich Protein (GLURP) and MSP3 [15], both of 
which have been identified as targets of naturally acquired malaria immunity [16, 17] and 
specific IgG antibodies that are broadly inhibitory [18, 19]. Phase I clinical trials have shown 
good tolerability, safety and immunogenicity of GMZ2 adjuvanted with aluminum hydroxide 
(Alum) in malaria-naïve adults [20] as well as in African adults and children [21, 22]. 
Functional anti-GMZ2 antibodies at levels comparable to those observed in naturally exposed 
individuals were generated [19], but vaccine efficacy (VE) under natural exposure has not 
been evaluated. 
Here, we report the first results of a multicenter phase 2 clinical trial to assess GMZ2/Alum 
vaccine efficacy in African children from Western, Central and East Africa.  
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2. Materials and methods  
2.1. Study Populations 
The trial was conducted in five sites with different transmission patterns. In Banfora and 
Sapone, Burkina Faso [23] and in Navrongo, Ghana, malaria transmission is intense and 
highly seasonal. In Iganga, Uganda [24], and Lambaréné, Gabon, transmission occurs 
throughout the year. Cohort studies were performed before the trial to assess the incidence of 
malaria. Additional details about the sites are provided in the Protocol (supplementary 
materials). 
 
2.2. Study design and ethics 
This was a randomized, controlled, multicenter, double blind phase 2 trial to measure VE of 
GMZ2/alum in African children. Participants were allocated in a 1:1 ratio to receive three 
doses of either GMZ2/Alum or the control vaccine (rabies, Verorab) four weeks apart, and 
were followed for six months. The study was performed in accordance with the protocol 
(Supplement), the International Conference on Harmonization, the Declaration of Helsinki in 
its 5th revision, and national regulatory requirements. The ethics committee and the regulatory 
authority of each country reviewed and approved the study (Supplement). An independent 
Data and Safety Monitoring Board reviewed the safety data (serious adverse events) during 
the trial. This trial is registered with PACTR, registration number: 
PACTR2010060002033537. 
 
2.3. Study participants 
Study participants were healthy children, aged 12–60 months, residing in the study areas and 
available for follow-up. They were not anemic (Hb<7g/dL) or malnourished (weight for age 
z-score <-2 - -3), and did not have signs of a chronic illness or renal or hepatic abnormality. 
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They had not taken immunosuppressive medication, immunoglobulin or blood products in the 
last three months, or another investigational drug or vaccine in the last month, and had no 
history of hypersensitivity to vaccines and no history of splenectomy. Routine vaccinations 
were given outside a 14 days interval before and after a dose of study vaccine. Written 
informed consent was obtained from the parents or legal guardian of each participant, signed 
by an impartial witness if they could not read. Families of participants were asked to report to 
the clinical team whenever a study-child was unwell. Blood samples were taken for 
microscopy at the health facilities from children with fever or history of fever. All disease 
episodes were treated according to national or international guidelines. Registered artemisinin 
combination therapies were used for treatment of uncomplicated malaria. Parenteral 
artesunate or quinine was used to treat severe malaria according to national guidelines. 
 
2.4. Randomization and masking 
Randomization at each site was done in randomly permuted blocks of 10 generated using 
Stata version 10. Children were screened and those who met eligibility criteria were assigned 
a randomization envelope in numerical sequence. Children were randomized to receive either 
100 μg GMZ2 (Novasep, Belgium), reconstituted in 0.5 ml adjuvant (Alum, Statens Serum 
Institut, Denmark) or rabies vaccine (Verorab, Sanofi Pasteur). All vaccine doses were given 
as intramuscular injections into the deltoid muscle, alternately in the left and right arms. 
Syringes were masked and the vaccinating nurse was not involved in any other activity in the 
trial. Safety was assessed after the first 40 children were vaccinated at each site before 
continuing recruitment. 
 
2.5. Outcomes 
9 
 
The primary endpoint was clinical malaria for 6-month after the first vaccination. Malaria 
was defined as asexual P. falciparum parasitemia of ≥5,000 parasites/μl with fever (tympanic 
temperature ≥38°C) or a history of fever in the previous 48 hours. Secondary endpoints 
included malaria with fever or history of fever and a parasite density >0, ≥500, ≥2,500, or 
≥20,000/uL; incidence of solicited local and general symptoms within seven days of 
vaccination and unsolicited adverse events at any time; anemia (Hb<7g/dL) at six months; 
and severe malaria, defined as hospitalization for at least 24 hours with malaria as primary 
diagnosis. Passive follow-up was used to capture malaria episodes. 
To assess safety, participants were directly observed for 30 minutes after each vaccine 
injection, followed by daily home visits for six days. On Day 7, a physician examined 
participants at the clinic. Following the third vaccine injection, monthly home visits were 
done to check that the child was still present in the study area and to capture adverse events 
(AE) and serious AEs (SAE) that were not actively reported to the clinical team. 
 
2.6. Laboratory methods 
Five ml of blood was collected by venipuncture into EDTA tubes for hematology and into 
dry tube for biochemistry. Hemoglobin was determined using a Hemocue analyzer at all sites. 
Full blood counts and biochemistry were done using calibrated automatic analyzers. P. 
falciparum parasitemia was assessed using two independent reads of Giemsa-stained thick 
blood smears at a 1000x magnification, followed by a third read in case of discordance 
(disagreement on positivity or a >2-fold difference in parasitemia). The number of parasites 
per µl of blood was calculated according to the measured leucocyte count. A slide was 
declared negative if no parasite was seen after microscopic examination of 200 high power 
fields. GMZ2-specific IgG antibody levels were determined by ELISA as previously 
described in detail using the vaccine antigen preparation for capture of antibodies [21]. 
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Antibody concentrations are given as titers normalized to a highly positive pool. A titer of 
one would mean the same anti-GMZ2 antibody concentration as in the pool, 0.1 a 10-fold 
lower concentration. 
 
2.7. Statistical methods 
Sample size was calculated to have at least 90% power for the According to Protocol (ATP) 
analysis if the VE was at least 30%, using a 5% significance level, allowing for 15% loss to 
follow-up or incomplete vaccination. All children who were randomized were included in the 
Intention to Treat (ITT) analysis, those who received three doses of either GMZ2 or rabies 
vaccine were included in the ATP analysis. Time at risk was calculated from randomization 
(ITT) or from the date of the third dose of vaccine (ATP), until six months after the date for 
the third dose. VE, defined as the percentage reduction in the number of malaria episodes, 
was calculated as 100x(1-R), where R is the hazard ratio estimated by Cox regression, with 
site as a stratification factor, and confidence interval calculated using a robust standard error 
to account for repeated episodes in the same child. Cases that occurred within 14 days of a 
previous episode were not counted. A Statistical Analysis Plan (Supplement) was prepared 
before database lock and unblinding. Subgroup analyses by site, age group and use of 
insecticide-treated nets (ITN) was planned. Completed paper case record forms were quality 
checked and transcribed into a database using eClinical eDM and eDC system version 5.0. 
Single data entry was used, with verification of the data entry by proof reading of selected 
areas combined with full proof reading of selected CRFs to verify accuracy. 
 
3. Results  
3.1. Participants 
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Between November 2010 and September 2011, 1849 children were enrolled (Figure 1, and 
Supplementary Figure S1). Demographics and other baseline characteristics were similar in 
the two groups although there was a slightly higher proportion of older children in the rabies 
vaccine group (Table 1 and supplementary Table S1). 
 
3.2. Efficacy 
During the six-month follow up, there were 1361 episodes of malaria with parasite density of 
≥5000 parasites per μL amongst those who received three doses of vaccine, 641 in the 
GMZ2/Alum group and 720 in the control group (Fig. 2). In the per-protocol analysis, VE, 
adjusted for age and site, was 13.6% (95% confidence interval [CI] 3.6%,23%, p-
value=0.009). In the ITT analysis, there were 1925 episodes of malaria with parasite density 
of ≥5000 parasites per μL, 920 in the GMZ2/Alum group and 1005 in the control group with 
age-adjusted VE of 11.3% (95% CI 2.5%,19%, p-value=0.013). Similar estimates were 
obtained when different parasite density cut-offs were used (Table 2). Similar estimates were 
also obtained when age was not included in the model (Table 2). There was no evidence that 
efficacy varied by site (Supplementary Table S2). The number of children with one or more 
episodes of malaria is listed in supplementary Table S3. VE (ATP), adjusted for age and site, 
from the Kaplan Meier estimates of the proportion with malaria was 7.63% (95% CI, 
0.95%,13.86%) and 6.36% (95% CI, 1.53 %,10.95%) in the ITT analysis. VE (ATP) was 
20% (4%,33%) in children 3-4yrs of age and 6% (-8%,18%) in children 1-2yrs of age, 
interaction P-value 0.112. In the ITT analysis the VE was 18% (5%, 30%) in children 3-4yrs 
of age and 3% (-10%, 14%) in children 1-2yrs of age, interaction p-value=0.057. The 
proportion of children with fever, at a given parasite density, was lower in the older age-
group than in younger children in both vaccine groups (odds ratio for fever adjusted for site 
0.72 (95%CI 0.59,0.89) (supplementary Figure S2). The distribution of parasite density 
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among cases treated for malaria was similar in the GMZ2/Alum and rabies vaccine groups 
(supplementary Figure S2). 
 
Thirty-two cases of severe malaria were reported in children who had received three doses of 
vaccine, 18 in the rabies group and 14 in the GMZ2/Alum group. In the ATP analysis, VE 
against severe malaria adjusted for age and site was 27% (95%CI -44%,63%) while in the 
ITT analysis, VE was 20% (95% CI -41%,55%). The prevalence of anemia after 6-months 
follow-up was similar (OR=2.96, 95% CI 0.60-14.7, p=0.185) in the GMZ2/Alum group 
(6/816) and in the rabies vaccine group (2/793). 
 
3.3. Safety and reactogenicity 
Vaccine doses were well tolerated (supplementary Tables S4 – S6). There were 17 
individuals in the rabies group and 29 in the GMZ2/Alum group with solicited, grade 3 AE 
within seven days of a dose. Of these, four in the rabies group (two induration and two fever 
≥39oC) and five in the GMZ2/Alum group (one swelling and four fever ≥39oC) were reported 
as related to the study vaccine. Three grade 3 unsolicited vaccine related AEs were reported 
within 28 days of a dose, two in the rabies group and one in the GMZ2/Alum group 
(supplementary Table S6). During the six months follow-up period post dose 3, five children 
died, two in the GMZ2/Alum group and three in the control group (Supplementary Table S7). 
There were 68 other SAEs (35 in the rabies group and 33 in the GMZ2/Alum group) most of 
these were malaria (Supplementary Table S8). Two of the SAEs were considered related to 
vaccination, both events in one individual who had received rabies vaccine. 
 
3.4. Immunogenicity 
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The mean titer of anti-GMZ2 antibodies increased 8-fold (95%CI 6.1,11) from baseline in 
children who received three doses of GMZ2/Alum. There was a greater increase in children 
1-2yrs old (14-fold increase, 95% CI 8.7, 23) compared to children 3-4yrs old (5.7-fold, 95% 
CI 4.0,8.2), however the smaller increase in older children was due to a higher baseline level 
of naturally acquired antibodies (Table 3) . At baseline, arithmetic mean GMZ2 IgG levels 
were 0.09 and 0.21 in the 1-2yrs and 3-4 yrs age groups, respectively (Table 3). A similar 
effect of age was also observed in the rabies vaccine group (Table 3). To investigate the 
association between the concentration of anti-GMZ2 IgG antibodies measured after the third 
vaccine dose (Day 84) and malaria incidence, children in the GMZ2/Alum group were 
divided into four groups based on the quartiles of the anti-GMZ2 antibody concentration 
(Table 4). Children with anti-GMZ2 antibody concentrations above the upper quartile had 
23% (95%CI 1.8%,39%; p-value=0.035) lower incidence of clinical malaria,  compared with 
children in the lowest quartile group. This association remains after adjusting for age-related 
exposure to P. falciparum malaria. 
 
4. Discussion 
GMZ2/Alum was well tolerated and immunogenic in children from West, Central, and East 
Africa. Although efficacy is too low for the vaccine to have a role in public health in its 
present form, the finding that the risk of acquiring clinical malaria decreased with increasing 
levels of GMZ2-specific antibodies, suggests that efficacy might improve if immunogenicity 
can be enhanced with improved formulations or a more potent adjuvant. Preclinical studies in 
Saimiri sciureus monkeys suggested that stronger adjuvants enhance both immunogenicity 
and protective efficacy of GMZ2 [25]. Whether novel formulations using stronger adjuvants 
may elicit significantly better protection against clinical disease remains to be investigated.  
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The worldwide dynamics of P. falciparum populations is complex and the distribution of 
different parasite strains differs from region to region and evolves over time possibly because 
of immune selection [26]. Multicenter trials in a range of different settings are therefore 
required to show that efficacy of vaccine candidates is not site dependent. We did not find 
evidence of variation in efficacy, although site effects cannot be ruled out, as the power for 
the interaction test was low. The limited antigenic variation observed in the GLURP and 
MSP3 regions included in the GMZ2 vaccine may facilitate the generation of broadly 
inhibitory antibodies as suggested in functional bioassays assay using geographically and 
genetically diverse P. falciparum isolates [18, 19]. These studies, together with a preclinical 
study using the GLURP component of GMZ2 [27], suggests that GMZ2 may generated a 
broad anti-parasitic immune response that covers more than a small number of isolates. This 
is particularly important in areas of high endemicity, where infections are usually complex. 
On the other hand, IgG antibodies against the components of GMZ2 may also control parasite 
multiplication through opsonic phagocytosis of P. falciparum merozoites [28]. Functional 
analyses of GMZ2 IgG from the present trial would be important to identify surrogate 
markers of protection [29]. 
 
GMZ2/Alum elicits higher protection in children 3-4 years of age compared to children 1-2 
years of age. The interaction with age may suggest that vaccine-induced antibodies act in 
concert with protective antibodies acquired through natural exposure [30] and/or are more 
functionally competent in terms of avidity and IgG subclass profile [31]. We did not find any 
evidence that efficacy waned during the six months of follow-up, however analysis of longer 
term follow up, which is planned, will be required to give a better estimate of duration of 
protection. Numerous immune-epidemiological studies have demonstrated an association 
between the level of antibodies against GLURP and MSP3 and protection from clinical 
15 
 
malaria [16, 17, 32]. In this trial, we found a relationship between concentration of vaccine-
induced antibodies and incidence of clinical malaria. Children in the GMZ2/Alum group with 
anti-GMZ2 IgG concentrations above the upper quartile had 23% fewer episodes of clinical 
malaria than children with in the lowest group This effect of high GMZ2 IgG antibodies was 
independent of age. In fact, there was an indication that children 1-2 yrs of age with low pre-
vaccination GMZ2 IgG levels responded strongly to vaccination, whereas older children with 
more exposure to P. falciparum showed a smaller boost of GMZ2 IgG responses. This is in 
accordance with our previous findings [20-22] and suggests that prior exposure to P. 
falciparum might diminish subsequent boosting by vaccination. Together, these observations 
suggest that an increased immunogenicity of GMZ2 may improve VE. The present vaccine 
formulation is based on Alum which is not as potent as more recently developed adjuvants. 
Notably, a formulation of RTS,S with Alum was not efficacious [33]. New formulations such 
as oil-in-water emulsions [34-36] may improve immunogenicity and efficacy of GMZ2. 
Efficacy of the RTS,S vaccine against severe disease appeared to be limited by rebound 
effects that occurred due to delayed acquisition of natural immunity [7]. Blood-stage vaccines 
might be less likely than pre-erythrocytic vaccines to interfere with acquisition of natural 
immunity as they do not prevent infection but this would need to be evaluated in larger trials. 
The safety and reactogenicity profile of GMZ2/Alum was good, consistent with previous 
clinical trials [20-22]. GMZ2 could be combined with other vaccines to improve protection 
[13]. Combining GMZ2 with transmission blocking antigens [27] could help reducing the 
spread of parasites, including potential escape mutants, in the population. Our results show 
that a safe and broadly reacting blood-stage malaria vaccine is possible, but more 
immunogenic formulations need to be evaluated. 
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Figure legends 
Figure 1. Trial profile. 1735 children received 3 doses of vaccine (867 Verorab and 868 
GMZ2) and were included in the per-protocol analysis. 809/867 (%) and 827/868 (%) 
respectively were seen at the scheduled 6 month visit. There were three allocation errors: one 
child randomized to receive rabies vaccine was given three doses of GMZ2, (this child was 
included in per-protocol analysis); two children, one randomized to rabies vaccine and the 
other to GMZ2, received mixed doses, these children were excluded from the per-protocol 
analysis but were included in ITT analysis. 
 
Figure 2. Timing of malaria episodes in each 2 vaccine group. The Nelson-Aalen estimate of 
the cumulative hazard (the mean number of episodes per child) in each group is shown 
against time since randomization. A) all age groups combined; B) children 1-2yrs of age; C) 
children 3-4 years of age. Time at risk for ITT analyses is from randomization until 3 months 
post dose 3, i.e. approximately 8 months. 
 
Supplementary Figure S1. Trial profile for each of the five sites presented in figures A-E. 
 
Supplementary Figure 2S. The probability of fever in the rabies vaccine (in blue) and 
GMZ2 group (in red) in relation to parasite density, in each age group in each site. Smoothed 
plots of the probability of fever were obtained using fractional polynomial logistic regression. 
Dashed lines show 90% confidence limits. The arrow shows the density associated with a 
50% probability of fever to facilitate comparison between the plots. There is no density 
corresponding to 50% probability of fever in Saphone. The distribution of parasite densities 
in the rabies vaccine group in each site and age group is shown as a histogram. 
Table 1: Characteristics of the trial participants at baseline. 
Variable Control GMZ2 
Number randomized 923 926 
Age in months (mean, range) 36.7 (12-60) 35.6 (11-60) 
Age group    
11-23 months 198 (22%) 201 (22%) 
24-35 months 217 (24%) 226 (24%) 
36-47 months 262 (29%) 307 (33%) 
48-60 months 242 (26%) 190 (21%) 
Gender: Male 502 (54%) 498 (54%) 
Bednet use* 395 (50%) 367 (45%) 
Temperature (mean, range) 36.7 (13-40.4) 36.7 (14-39.7) 
Weight in kg (mean, range) 13.1 (0.9 - 95) 12.8 (7 -41) 
Weight for age z-score** (mean, range) -0.7 (-10.5 – 36.2) -0.7 (-3.5 – 16.1) 
Biochemical and haematological variables (mean, range) 
White blood cell count  (10^3/uL) 9.5 (1.8 - 67.7)  9.8 (2.1 - 46.7)  
Red blood cell count (10^6/uL) 4.5 (1.8 -9.5)  4.5 (1.8 - 10.1)  
Haemoglobin (g/dL) 10.5 (6.4 - 14.2)  10.5 (6.2 - 14.1)  
Haematocrit (%) 32.7 (8.4 - 41.9)  32.7 (11.3 - 44.5)  
Platelets (10^3/uL) 328 (14 - 999)  327 (11 - 999)  
Creatinine (umol/L) 30.5 (5-92)  30.3 (0-96.1)  
Total Bilirubin (umol/L) 7.3 (1.1-64)  7.5 (0-47)  
ALT** (IU/L) 18.6 (3.5-137)  19.0 (0-206)  
ASAT (IU/L) 37.9 (7-278)  37.6 (0.5 - 181)  
Alkaline Phosphatase** (IU/L) 268 (113 - 700)  261 (0-700)  
Anti-GMZ2 IgG titre (mean EU per µl)## 0.153 0.153 
 
*Slept under a treated net the night before the survey. Note bednet use was not measured at baseline 
but after the six-month visit. 
*ALT was not measure in Uganda 
**Alkaline Phosphatase was not measured in the two Burkina Faso sites or Gabon 
## At baseline, 51% of participants had detecTable anti-GMZ2 antibodies (mean 0.153 enzyme-
linked immunosorbent assay units (EU) per µl), this varied by site with highest levels in Sapone 
(mean 0.3) and lowest in Gabon (mean 0.04). 
Table 2: Vaccine efficacy at different parasitemia threshold densities ITT and ATP populations  
  
Rabies Vaccine              GMZ2 Vaccine efficacy  (95%CI) 
age 
interaction 
p-value 
No. of 
malaria 
episodes 
Mean no.  
episodes 
per child 
No. of 
malaria 
episodes 
Mean no.  
episodes per 
child 
unadjusted, site as 
strata 
adjusted for age (site as 
strata) 
Malaria with documented fever or history of fever and parasitaemia at any density >0/μL  
ITT 1264 1.37 1204 1.30 6.1% (-1.9% - 13.5%) 7.2% (-0.6% - 14.4%) 0.062 
ATP 894 1.03 842 0.97 6.3% (-3.1% - 14.7%) 7.9% (-1.1% - 16.1%) 0.136 
Malaria with documented fever or history of fever and parasite density >5000/μL 
ITT 1005 1.09 920 0.99 9.7% (0.4% - 18.1%) 11.3% (2.5% - 19.3%) 0.057 
ATP 720 0.83 641 0.74 11.3% (0.8% - 20.7%) 13.6% (3.6% - 22.5%) 0.112 
Malaria with documented fever or history of fever and parasite density >20,000/μL 
ITT 777 0.84 718 0.78 8.7% (-2.1% - 18.6%) 10.6% (0.1% - 21%) 0.043 
ATP 563 0.65 501 0.58 11.3% (-1.1% - 22.1%) 13.7% (2.0% - 24.1%) 0.075 
 
Table 3: Anti-GMZ2 IgG responses in children 1-2 yrs and 3-4 yrs of age in the two vaccine groups. 
Arithmetic mean titres (SD) at baseline and on day 84 (ATP population). 
 
 Rabies vaccine  
mean(SD) 
Ratio  
(95%CI) 
GMZ2 
mean (SD) 
Ratio  
(95%CI) 
Age group Day 0 Day 84 Day84/Day0 Day 0 Day 84 Day84/Day0 
1-2yrs 0.07 (0.24) 0.15 (0.47) 2.2 (1.4,3.7) 0.09 (0.38) 1.21 (2.53) 14 (8.7,23) 
 
3-4yrs 0.22 (0.85) 0.35 (1.32) 1.6 (0.95,2.6) 0.21 (0.72) 1.21 (2.01) 5.7 (4.0,8.2) 
 
Ratio  
(95%CI) 
3.3 
(2.0,5.5) 
2.3 
(1.4,3.8) 
 2.5  
(1.4,4.2) 
1.0 
(0.77,1.3) 
 
 
Table 4: Association between GMZ2 IgG titre measured on day 84, and the incidence of 
malaria in each vaccine group. 
 GMZ2 Rabies vaccine 
 
GMZ2 IgG titre* 
No. of 
children 
Hazard ratio# 
(95%CI) 
 
P-value 
No. of 
children 
Hazard ratio# 
(95%CI) 
 
P-value 
1 201 1  654 1  
0.21-0.54 201 0.85 (0.69,1.1) 0.147 70 1.1 (0.82,1.4) 0.696 
0.54-1.3 201 0.94 (0.75,1.2) 0.606 39 0.84 (0.54,1.3) 0.423 
≥1.3 200 0.77 (0.61,0.98) 0.035 34 0.68 (0.44,1.1) 0.083 
 
*4 groups defined by quartiles of GMZ2 IgG titre in the GMZ2 group.  
# adjusted for age and site. 
  
Figure 1: Trial profile. 1735 children received 3 doses of vaccine (867 Verorab and 868 GMZ2) and 
were included in the per-protocol analysis. 809/867 (%) and 827/868 (%) respectively were seen at 
the scheduled 6 month visit. There were three allocation errors: one child randomized to receive 
rabies vaccine was given three doses of GMZ2, (this child was included in per-protocol analysis); 
two children, one randomized to rabies vaccine and the other to GMZ2, received mixed doses, 
these children were excluded from the per-protocol analysis but were included in ITT analysis. 
 
 1 
Figure 2. Timing of malaria episodes in each vaccine group. 2 
The Nelson-Aalen estimate of the cumulative hazard (the mean number of episodes per 3 
child) in each group is shown against time since randomization.  A) all age groups 4 
combined; B) children 1-2yrs of age; C) children 3-4 years of age. Time at risk for ITT 5 
analyses is from randomization until 3 months post dose 3, i.e. approximately 8 months. 6 
 7 
 
 
0.
00
0.
20
0.
40
0.
60
0.
80
1.
00
1.
20
Cu
m
u
la
tiv
e
 
ha
za
rd
923 912 905 902 898 897 892 891 687GMZ2
923 900 890 884 882 880 871 867 655Rabies vaccine
Number at risk
0 1 2 3 4 5 6 7 8
Months since randomisation
Rabies vaccine GMZ2
 
0.
00
0.
20
0.
40
0.
60
0.
80
1.
00
1.
20
Cu
m
u
la
tiv
e 
ha
za
rd
425 420 417 417 414 414 411 410 311GMZ2
415 397 389 386 385 384 378 376 286Rabies vaccine
Number at risk
0 1 2 3 4 5 6 7 8
Months since randomisation
Rabies vaccine GMZ2
 
0.
00
0.
20
0.
40
0.
60
0.
80
1.
00
1.
20
Cu
m
u
la
tiv
e 
ha
za
rd
468 463 459 456 455 454 452 452 353GMZ2
481 476 474 471 470 469 466 464 349Rabies vaccine
Number at risk
0 1 2 3 4 5 6 7 8
Months since randomisation
Rabies vaccine GMZ2
 
A B 
C 
1 
 
Supplementary Table S1: Baseline characteristics by randomisation arm per site 
 
Banfora Sapone Gabon Ghana Uganda 
Variable Control GMZ2 Control GMZ2 Control GMZ2 Control GMZ2 Control GMZ2 
Number 
randomized 290 290 150 150 256 256 100 100 127 130 
Age in months 
(mean,range) 36.2 (12-59) 
34.6 (12-
59) 
35.6 (12-
59) 
34.7 (12-
58) 
35.9 (12-
59) 
34.4 (11-
59) 
37.6 (12-
60) 
37.5 (12-
60) 
39.7 (12 - 
59) 
39.7 (13 - 
59) 
Age group (number 
(%)): 11-23 months 53 (18%) 53 (18%) 37 (25%) 44 (29%) 69 (27%) 68 (27%) 27 (27%) 24 (24%) 12 (9%) 12 (9%) 
24-35 months 84 (29%) 102 (35%) 34 (23%) 27 (18%) 55 (22%) 55 (22%) 13 (13%) 15 (15%) 31 (24%) 27 (21%) 
36-47 months 93 (32%) 90 (31%) 41 (27%) 43 (29%) 53 (21%) 82 (32%) 28 (28%) 34 (34%) 47 (37%) 58 (45%) 
48-60 months 60 (21%) 45 (16%) 38 (25%) 36 (24%) 76 (30%) 50 (20%) 31 (31%) 26 (26%) 37 (29%) 33 (25%) 
Gender: Male 152 (52%) 151 (52%) 87 (58%) 80 (53%) 143 (56%) 138 (54%) 49 (49%) 55 (55%) 71 (56%) 74 (57%) 
Bednet use, sleep 
under a treated 
net*: Yes 163 (64%) 165 (63%) 60 (47%) 51 (38%) 74 (39%) 71 (37%) 78 (79%) 70 (71%) 20 (18%) 10 (8%) 
Temperature 
(mean, range) 
36.7 (36-
39.4) 
36.6 (36-
38.4) 
36.9 (36.1 
– 38.1) 
36.8 (36 – 
37.6) 
37.2 (35.2 
– 40.4) 
37.2 (36-
39.7) 
36.3 (35.6 
– 37.3 
36.3 (36 – 
37.7) 
36.2 (13 – 
38.9) 
36.2 (14 – 
38.2) 
Weight in kg (mean, 12.9 (6.9-95) 12.3 (7.6 – 12.4 (7.6 – 12.5 (7.4 – 13.2 (7.4 – 12.7 (7.5 – 13.1 (6.2 – 13.3 (7-41) 14.3 (0.9 - 14.4 (8 - 
2 
 
range) 18.7) 36.7) 37.4) 21.6) 19.6) 19.3) 25) 22) 
Biochemical and haematological variables (mean, range) 
  White blood cell 
count (10^3/uL) 
9.5 (4.4 - 
67.7) 
9.4 (4.3 – 
21.4) 
9.7 (5 - 
22.6) 
10.1 (4.5 - 
46.7) 
10.0 (1.8 - 
21.6) 
10.5 (2.1 - 
29.9) 
8.8 (4.3 - 
15.7) 
9.4 (5.6 – 
20.9) 
8.9 (3.2 - 
31.9) 
9.4 (4.8 - 
18.6) 
Red blood cell 
count (10^6/uL) 4.5 (2.9 - 5.9) 
4.5 (3.2 – 
6.7) 
4.5 (3.5 - 
5.6) 4.5 (3.0 - 6) 
4.5 (1.8 - 
5.9) 
4.5 (1.8 - 
7.4) 
4.4 (3.3 – 
6.1) 
4.4 (3.3 - 
5.9) 
4.4 (2.8 - 
9.5) 
4.4 (2.9 - 
10.1) 
Haemoglobin (g/dL) 
10.5 (7.3 - 
13.7) 
10.5 (7.4 - 
13.5) 
11.0 (7.9 - 
14.2) 
10.9 (7.6 - 
14.1) 
10.2 (7.3 - 
12.9) 
10.1 (7.4 - 
13.6) 
10.4 (6.4 - 
12.6) 
10.4 (6.2 - 
12.5) 
10.5 (7 - 
13.6) 
10.8 (8 - 
13.6) 
Haematocrit (%) 
33.4 (21.8 - 
40.3) 
33.3 (23.9 - 
42.4) 
33.2 (24.8 - 
40.3) 
33.0 (25.1 - 
40.4) 
31.8 (14.2 - 
38.9) 
31.6 (14.2 - 
44.5) 
32.9 (23 - 
40) 
33.1 (23 - 
40) 
32.1 (8.4 - 
41.9) 
32.9 (11.3 
- 42) 
Platelets (10^3/uL) 
359 (40.2 - 
999) 
344 (77.8 - 
814) 
293 (64.9 - 
566) 
302 (10.8 - 
835) 
336 (14-
658) 
343 (27-
999) 
335 (82 - 
807) 
331 (127 - 
688) 
277 (40 - 
637) 
287 (72 - 
628) 
Creatinine (umol/L) 
29.5 (6.3 - 
55.3) 
29.1 (4.6 - 
55) 
35.4 (16.9 - 
63) 
35.1 (14 - 
69) 
23.4 (5-
44.2) 22.9 (5-45) 
54.1 (9 - 
92) 
55.7 (31.7 - 
96.1) 
22.3 (11.3 - 
41.9) 
22.2 (0 - 
37.3) 
Total bilirubin 
(umo l/L) 
7.8 (2.5 - 
26.7) 
8.0 (1.0 - 
28.9) 
7.2 (2.5 - 
19.8) 
7.8 (2.5 - 
25.7) 7.6 (3-18) 8.2 (2-47) 
7.1 (1.1 - 
64) 
6.1 (1.5 - 
39.8) 
5.9 (1.3 - 
54) 
6.0 (0 - 
24.1) 
ALT** (IU/L) 
17.6 (3.5 - 
63.2) 
16.5 (0-
68.7) 
24.1 (8 - 
137) 
24.8 (6 - 
154) 14.3 (6-67) 14.3 (6-73) 
24.0 (5.7 - 
104.4) 
28.6 (7.5 - 
206.1) - - 
ASAT (IU/L) 42.1 (23.3 - 41.6 (1.1- 41.5 (20 - 42.4 (8 - 31.0 (7-74) 31.6 (15- 38.1 (22.9 - 40.2 (19.9 - 36.4 (18.4 - 32.6 (0.5 - 
3 
 
 
*Slept under a treated net the night before the survey. Note bednet use was not measured at baseline but after the 6 month visit. 
**ALT was not measured in Uganda 
***Alkaline Phosphatase was not measured in the 2 Burkina Faso sites or Gabon 
  
93.7) 86.9) 151) 138) 122) 96.2) 181.4) 278) 52.8) 
Alkaline 
Phosphatase*** 
(IU/L) - - - - - - 
311 (167 - 
613) 
285 (141-
483) 
236 (113 - 
700) 
243 (0 - 
700) 
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Supplementary Table S2. Vaccine efficacy by site at primary outcome, 6 months: Fever/history of fever and parasite density >5000/uL 
 
 
ITT ATP 
Site 
Rabies 
vaccine GMZ2 
Hazard Ratio VE Rabies 
vaccine GMZ2 
Hazard Ratio VE 
(95%CI) (95%CI) (95%CI) (95%CI) 
  Rate (No episodes/PYAR):     Rate (No episodes/PYAR):     
Banfora 2.72 
(497/182.7) 
2.42 
(444/183.4) 
0.89  
(0.77 - 1.02) 
11%  
(-2%-23%) 
3.01 
(403/133.8) 
2.59 
(348/134.3) 
0.86  
(0.74 - 1.01) 
14%  
(-1% - 26%) 
Lambarene 0.45 
(70/155.2) 
0.44 
(71/161.0) 
0.98  
(0.68 - 1.41) 
2%  
(-41% - 32%) 
0.41 
(45/109.4) 
0.34 
(38/110.8) 
0.83  
(0.54 - 1.29) 
17%  
(-29% - 46%) 
Navrongo 1.04 
(67/64.4) 
0.95 
(61/64.5) 
0.91  
(0.63 - 1.31) 
9%  
(-31% - 37%) 
0.98 
(49/50.0) 0.92 (45/49.0) 
0.94  
(0.61 - 1.45) 
6%  
(-45% - 39%) 
Sapone 2.29 
(214/93.5) 
2.18 
(210/96.1) 
0.96  
(0.78 - 1.17) 
4%  
(-17% - 22%) 
1.93 
(137/70.9) 
1.88 
(133/70.9) 
0.97  
(0.76 - 1.24) 
3%  
(-24% - 24%) 
Iganga 1.79 
(147/82.2) 
1.57 
(132/84.3) 
0.88  
(0.68 - 1.14) 
12%  
(-14% - 32%) 
1.30 
(81/62.1) 
1.17  
(75/63.9) 
0.90  
(0.65 - 1.25) 
10%  
(-25% - 35%) 
Pooled 1.72 
(995/578.1) 
1.56 
(918/589.3) 
0.91  
(0.83 - 1.00) 
9%  
(0% - 17%) 
1.68 
(715/426.3) 
1.49 
(639/428.8) 
0.89  
(0.80 - 0.99) 
11%  
(1% - 20%) 
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Supplementary Table S3: Number of malaria episodes experienced by children during 6-
month follow-up. 
  ITT ATP 
Number of 
episodes Number of children Number of children 
Parasitaemia 
>5000 
Rabies 
Vaccine GMZ2 
Rabies 
Vaccine GMZ2 
0 408 435 451 466 
1 237 246 219 255 
2 139 126 118 82 
3 87 72 54 44 
4 34 33 23 16 
5 15 10 1 4 
6 3 4 1 1 
Total 923 926 867 868 
 
  
6 
 
Adverse Events 
Supplementary Table S4: Solicited local symptoms: (within 7 days of the dose) by severity 
  Rabies vaccine GMZ2  
  Dose 1 
N=921 
Dose 2 
N=895 
Dose 3 
N=867 
After 
any 
dose 
N=921 
Dose 1 
N=925 
Dose 2 
N=900 
Dose 3 
N=867 
After 
any 
dose 
N=925 
Any solicited 
local adverse 
event 
Number of individuals affected Number of individuals affected 
140 
(15%) 
89 
(10%) 
85 
(10%) 
217 
(24%) 
188 
(20%) 
109 
(12%) 
95 
(11%) 
268 
(29%) 
Grade 3 1 1 0 2 0 0 1 1 
Pain: Any  114 
(12%) 
67 (7%) 77 (9%) 180 
(20%) 
156 
(17%) 
92 
(10%) 
74 (9%) 224 
(24%) 
Grade 3 0 0 0 0 0 0 0 0 
Swelling: Any  26 (3%) 15 (2%) 13 (1%) 49 (5%) 43 (5%) 14 (2%) 13 (2%) 64 (7%) 
Grade 3 0 0 0 0 0 0 1 1 
Induration: Any  23 (2%) 11 (1%) 8 (1%) 41 (4%) 33 (4%) 18 (2%) 20 (2%) 63 (7%) 
Grade 3 1 1 0 2 0 0 0 0 
Erythema: Any  1 
(<1%) 
0 (0%) 0 (0%) 1 (<1%) 4 (<1%) 0 (0%) 0 (0%) 4 (<1%) 
Grade 3 0 0 0 0 0 0 0 0 
Pruritus: Any 1 
(<1%) 
6 (1%) 0 (0%) 6 (1%) 3 (<1%) 2 (<1%) 1 (<1%) 6 (1%) 
Grade 3 0 0 0 0 0 0 0 0 
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Supplementary Table S5: Solicited general symptoms: (within 7 days of the dose) 
  Rabies Vaccine GMZ2  
  
Dose 1 
N=921 
Dose 2 
N=895 
Dose 3 
N=867 
After 
any 
dose 
N=921 
Dose 1 
N=925 
Dose 2 
N=900 
Dose 3 
N=867 
After 
any 
dose 
N=925 
Any solicited 
general adverse 
event 
Number of individuals affected Number of individuals affected 
81 (9%) 65 (7%) 68 (8%) 
183 
(20%) 
98 
(11%) 85 (9%) 65 (7%) 
216 
(23%) 
Any with 
information on 
relation 65 (7%) 53 (6%) 51 (6%) 
147 
(16%) 
81 
(9%) 67 (7%) 53 (6%) 
179 
(19%) 
Related to study 
vaccine 11 14 12 35 15 15 14 39 
Grade 3 related 1 0 1 2 1 3 0 4 
Fever: Any  26 (3%) 32 (4%) 
36 
(10%) 
88 
(10%) 
37 
(4%) 35 (4%) 47 (5%) 
110 
(12%) 
Related to study 
vaccine 5 12 10 27 12 14 13 36 
Grade 3 related 1 0 1 2 1 3 0 4 
Irritability: Any  
4 
(<1%) 6 (1%) 
1 
(<1%) 11 (1%) 8 (1%) 8 (1%) 2 (<1%) 17 (2%) 
Related to study 
vaccine 1 0 0 1 1 2 0 3 
Grade 3 related 0 0 0 0 0 0 0 0 
Drowsiness: Any  8 (1%) 6 (1%) 4 17 (2%) 14 8 (1%) 2 (<1%) 23 (2%) 
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(<1%) (2%) 
related 1 0 0 1 2 2 0 4 
Grade 3 related 0 0 0 0 0 0 0 0 
Loss of appetite:  
Any  17 (2%) 10 (1%) 6 (1%) 32 (3%) 
29 
(3%) 25 (3%) 6 (1%) 57 (6%) 
Related to study 
vaccine 2 1 1 4 4 2 1 7 
Grade 3 related 0 0 0 0 0 0 0 0 
Diarrhoea: Any  29 (3%) 13 (1%) 14 (2%) 48 (5%) 
21 
(2%) 16 (2%) 5 (1%) 40 (4%) 
Related to study 
vaccine 4 1 2 7 1 1 1 3 
Grade 3 related 0 0 0 0 0 0 0 0 
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Supplementary Table S6: Unsolicited adverse events by vaccine group and dose (within 28 
days of the dose): 
  Rabies vaccine GMZ2 
 Any 
unsolicited 
adverse 
event 
Dose 1 
N=921 
Dose 2 
N=895 
Dose 3 
N=867 
After any 
dose 
N=921 
Dose 1 
N=925 
Dose 2 
N=900 
Dose 3 
N=867 
After any 
dose 
N=925 
 
Number affected with at least one event 
(%) 
Number affected with at least one event 
(%) 
Any 
552 
(60%) 
458 
(51%) 
484 
(56%) 
810 
(88%) 
540 
(58%) 
481 
(53%) 
483 
(56%) 
814 
(88%) 
Related  14 (2%) 11 (1%) 6 (1%) 29 (3%) 29 (3%) 14 (2%) 12 (1%) 51 (6%) 
Grade 3 
related 1 0 1 2 0 0 1 1 
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Supplementary Table S7: Line listing of volunteers who died. 
Subject 
id 
Randomisation 
group 
Event 
start date 
Date last 
vaccination 
Time since 
last 
vaccination 
(days) Age Sex Term 
0000364 Rabies Vaccine 
13/10/201
1 05/07/2011 100 25 Male 
SUDDEN 
DEATH 
0000376 Rabies Vaccine 
11/11/201
1 07/07/2011 127 18 Female DROWNING 
L1250-8 Rabies Vaccine 
02/06/201
1 03/01/2011 150 56 Male 
MALARIA, 
CONVULSIONS 
L1701-3 GMZ2 
19/12/201
1 06/09/2011 104 12 Female PNEUMONIA 
M0032-9 GMZ2 
25/08/201
1 07/07/2011 49 17 Female 
SEVERE 
MALARIA 
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Supplementary Table S8: Line listing of all volunteers with severe malaria. 
Subject 
id Site 
Randomisation 
group 
Event 
start date 
Date last 
vaccination 
Time since 
last 
vaccination 
(days) 
Age 
(yrs) Sex Main condition Additional conditions reported Outcome 
0000012 Banfora Rabies Vaccine 19/10/2011 28/06/2011 113 2 M Malaria Malaria Pneumopathy/ 
Recovered/ 
Resolved 
0000013 Banfora GMZ2 16/09/2011 28/06/2011 80 2 F 
Malaria Severe 
Malaria Convulsions/ 
Recovered/ 
Resolved 
0000095 Banfora GMZ2 17/06/2011 31/05/2011 17 2 M Malaria Malaria Vomiting/ 
Recovered/ 
Resolved 
0000118 Banfora Rabies Vaccine 03/09/2011 29/06/2011 66 2 F 
Malaria Malaria 
(failure of oral 
medication) / 
Recovered/ 
Resolved 
0000245 Banfora GMZ2 22/11/2011 02/07/2011 143 2 F 
Malaria 
Uncomplicated 
malaria associated 
to bronchitis with 
inability to take 
treatment per os Bronchitis/ 
Recovered/ 
Resolved 
0000262 Banfora Rabies Vaccine 28/05/2011 04/05/2011 24 3 M 
Malaria Severe 
malaria Convulsions/ 
Recovered/ 
Resolved 
0000298 Banfora Rabies Vaccine 03/09/2011 02/07/2011 63 5 M 
Malaria 
Uncomplicated 
malaria associated 
to generalizes 
edema syndrom Edema/ 
Recovered/ 
Resolved 
0000454 Banfora GMZ2 03/10/2011 05/07/2011 90 2 M 
Malaria Severe 
Malaria / 
Recovered/ 
Resolved 
0000478 Banfora GMZ2 02/06/2011 14/05/2011 19 3 M Malaria Malaria / 
Recovered/ 
Resolved 
0000541 Banfora Rabies Vaccine 30/06/2011 09/06/2011 21 2 M 
Malaria Severe 
malaria Lethargic/ 
Recovered/ 
Resolved 
0000616 Banfora Rabies Vaccine 17/07/2011 11/07/2011 6 2 M 
Malaria Severe 
malaria Lethargic/ 
Recovered/ 
Resolved 
0000649 Banfora Rabies Vaccine 07/09/2011 08/08/2011 30 1 M 
Malaria Severe 
malaria Anemia/Pneumonia 
Recovered/ 
Resolved 
0000658 Banfora GMZ2 13/01/2012 08/08/2011 158 2 M 
Inguinal hernia 
strangulated 
Inguinal hernia 
strangulated Malaria/Fever 
Recovered/ 
Resolved 
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0000678 Banfora GMZ2 04/07/2011 27/06/2011 7 3 M 
Malaria Severe 
malaria Hemoglobinuria/ 
Recovered/ 
Resolved 
0000685 Banfora GMZ2 24/10/2011 24/08/2011 61 0 M 
Malaria Severe 
malaria Anemia/ 
Recovered/ 
Resolved 
0000736 Sapone Rabies Vaccine 17/09/2011 16/08/2011 32 3 M 
Malaria Severe 
malaria Fever/Convulsions 
Recovered/ 
Resolved 
0000737 Sapone Rabies Vaccine 10/11/2011 16/08/2011 86 0 M 
Malaria Severe 
malaria Fever/Convulsions 
Recovered/ 
Resolved 
0000780 Sapone Rabies Vaccine 20/09/2011 20/08/2011 31 3 F 
Malaria Severe 
malaria Fever/Respiratory distress 
Recovered/ 
Resolved 
0000796 Sapone GMZ2 10/09/2011 17/08/2011 24 4 M 
Malaria Severe 
malaria Vomiting/Fever 
Recovered/ 
Resolved 
0000857 Sapone GMZ2 26/09/2011 19/08/2011 38 3 M Malaria Malaria / 
Recovered/ 
Resolved 
0000935 Sapone GMZ2 12/01/2012 19/08/2011 146 3 F Malaria Malaria Fever/Vomiting/Convulsions/ 
Recovered/ 
Resolved 
0000986 Sapone Rabies Vaccine 06/12/2011 19/08/2011 109 1 M Malaria Malaria Fever/Vomiting 
Recovered/ 
Resolved 
0001047 Sapone GMZ2 11/07/2011 24/06/2011 17 2 M Malaria Malaria Respiratory distress/Convulsions 
Recovered/ 
Resolved 
0001069 Sapone GMZ2 14/08/2011 20/07/2011 25 4 M Malaria Malaria Bronchitis/ 
Recovered/ 
Resolved 
0001079 Sapone Rabies Vaccine 12/11/2011 20/08/2011 84 3 M Malaria Malaria 
Anemia/Respiratory 
distress/Convulsion/ 
Recovered/ 
Resolved 
L1223-3 Lambarene Rabies Vaccine 26/03/2011 04/01/2011 81 4 F Malaria Malaria Fever/ 
Recovered/ 
Resolved 
L1309-0 Lambarene Rabies Vaccine 15/02/2011 28/01/2011 18 3 F Malaria Malaria 
Tachycardia/Tachypnoea/Runny 
nose/Fever/Vomiting/Cough 
Recovered/ 
Resolved 
L1364-1 Lambarene Rabies Vaccine 23/01/2011 12/01/2011 11 4 F Malaria Malaria Fever/ 
Recovered/ 
Resolved 
L1386-2 Lambarene Rabies Vaccine 21/01/2011 12/01/2011 9 3 M Malaria Malaria Fever/ 
Recovered/ 
Resolved 
L1435-9 Lambarene Rabies Vaccine 21/09/2011 28/03/2011 177 5 F Malaria Malaria Fever/ 
Recovered/ 
Resolved 
L1462-7 Lambarene Rabies Vaccine 13/09/2011 24/03/2011 173 4 F Malaria Malaria 
Fever/Vomiting/Diarrhoea/Appetite 
lost 
Recovered/ 
Resolved 
L1499-8 Lambarene Rabies Vaccine 02/06/2011 08/04/2011 55 4 F Malaria Malaria Gastroenteritis/Ear infection 
Recovered/ 
Resolved 
L1639-0 Lambarene GMZ2 20/05/2011 28/04/2011 22 2 F Malaria Malaria Bronchitis/Fever 
Recovered/ 
Resolved 
L1649-4 Lambarene GMZ2 13/09/2011 03/06/2011 102 0 F Malaria Malaria Fever/Convulsion 
Recovered/ 
Resolved 
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L1691-2 Lambarene Rabies Vaccine 23/12/2011 25/08/2011 120 1 F Malaria Malaria Fever/Pallor/Dyspnea/ 
Recovered/ 
Resolved 
L1707-1 Lambarene Rabies Vaccine 11/12/2011 05/09/2011 97 2 M Malaria Malaria Bronchitis/Cough/Febrile convulsion/ 
Recovered/ 
Resolved 
M0009-4 Iganga GMZ2 24/11/2011 25/07/2011 122 0 M 
Malaria severe 
malaria with URTI 
URTI (upper respiratory tract 
infection)/Fever/Cough/Convulsion 
Recovered/ 
Resolved 
M0027-6 Iganga GMZ2 28/11/2011 25/07/2011 126 3 M 
Malaria Severe 
Malaria Anemia/Fever/Anorexia/Vomiting 
Recovered/ 
Resolved 
M0065-7 Iganga Rabies Vaccine 16/05/2011 13/05/2011 3 1 F 
Malaria severe 
Malaria with 
dehydration Dehydration/Fever/Vomiting/ 
Recovered/ 
Resolved 
M0084-9 Iganga GMZ2 26/10/2011 25/07/2011 93 1 M 
Malaria clinical 
Malaria with URTI 
URTI (upper respiratory tract 
infection)/Fever/Cough/ 
Recovered/ 
Resolved 
M0091-8 Iganga Rabies Vaccine 01/10/2011 08/07/2011 85 2 F Malaria Malaria 
Cough/Labored breathing/Nasal 
flaring/ 
Recovered/ 
Resolved 
M0188-0 Iganga Rabies Vaccine 31/10/2011 27/07/2011 96 3 M 
Malaria severe 
Malaria with 
dehydration Dehydration/Fever/Vomiting/Diarrhoea 
Recovered/ 
Resolved 
M0253-0 Iganga GMZ2 26/09/2011 29/07/2011 59 2 M Malaria Malaria Pneumonia/Fever/Cough/ 
Recovered/ 
Resolved 
N1877-4 Navrongo GMZ2 23/10/2011 29/07/2011 86 3 M 
Malaria Severe 
Malaria / 
Recovered/ 
Resolved 
N1928-3 Navrongo Rabies Vaccine 03/07/2011 07/06/2011 26 0 F Malaria Malaria Diarrhea/Fever/Vomiting/Appetite lost 
Recovered/ 
Resolved 
N1950-1 Navrongo GMZ2 14/07/2011 06/07/2011 8 2 F Malaria Malaria Fever/ 
Recovered/ 
Resolved 
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Supplementary Figure S1: Trial profile for each of the five sites presented in figures A-E 
A: Burkina Faso – Banfora  
 
 
B: Gabon - Lamberéné
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C: Ghana - Navrongo
 
 
D: Burkina Faso – Sapone
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E: Uganda – Iganga 
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Supplementary Figure 2S: The probability of fever in the rabies vaccine (in blue) and GMZ2 
group (in red) in relation to parasite density, in each age group in each site. 
 
Smoothed plots of the probability of fever were obtained using fractional polynomial logistic 
regression. Dashed lines show 90% confidence limits. The arrow shows the density 
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associated with a 50% probability of fever to facilitate comparison between the plots. There 
is no density corresponding to 50% probability of fever in Saphone. The distribution of 
parasite densities in the rabies vaccine group in each site and age group is shown as a 
histogram.  
